Pharma industry challenges Canada’s drug pricing plan
Innovative Medicines Canada, an association that represents drugmakers in Canada, has challenged the overhaul of Canada’s drug-pricing regime.
Novartis and BenevolentAI sign AI oncology deal
Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.
University can’t invoke state immunity to avoid venue transfer: Fed Circuit
State sovereignty principles don’t give the Board of Regents of the University of Texas the right to bring a lawsuit in an improper venue, according to the US Court of Appeals for the Federal Circuit.
Big pharma’s reputation sinks to ‘lowest-ever’ point
Americans now hold less regard for big pharma than any other industry, according to a poll from US analytics company Gallup.
Lupin and Boehringer enter $720m anti-cancer drug partnership
Indian drugmaker Lupin and German pharma company Boehringer Ingelheim have formed an alliance to develop a therapy for patients with difficult-to-treat cancers.
LSIPR webinar: CAR-T trends show increased filing for narrower tech, says HGF partner
CAR-T cells have achieved hugely-positive outcomes in treating forms of cancer that are otherwise difficult to treat.
Vertex to buy diabetes biotech firm for $950m
US-based Vertex Pharmaceuticals has announced it will pay $950 million to acquire Semma Therapeutics, a biotechnology company focused on researching a cure for Type 1 diabetes.
No-deal Brexit could ‘irreparably’ harm NHS and delay drugs: BMA
Leaving the EU without a deal in place could “irreparably” harm the UK’s National Health Service and lead to delays in new products being bought to market in the country, according to the British Medical Association.
Gene-editing alliance releases bioethical framework
An alliance of companies that use gene-editing technologies has released a bioethical framework, as controversy over gene-editing continues.
Pinsent Masons hires Fieldfisher’s co-head of life sciences
Nicole Jadeja, the former co-head of life sciences at Fieldfisher, has joined Pinsent Masons as a partner in its London office.
